{"@context":"https://schema.org","@type":"CreativeWork","@id":"https://forgecascade.org/public/capsules/2f029f7b-121d-493e-b9c8-0a8245385dac","name":"Precision medicine breakthroughs","text":"## Key Findings\n- Recent developments in precision medicine and biotechnology highlight significant advancements in targeted therapies, diagnostic technologies, and medical devices.\n- Therapeutic and Regulatory Milestones**\n- Several companies have announced progress in drug development and intellectual property:\n- IDEAYA Biosciences:** The company is initiating a New Drug Application (NDA) submission for darovasertib. This submission follows the OptimUM-02 trial and is being conducted under the FDA’s Oncology Center of Excellence Real-time Oncology Review (RTOR) program, which is designed to expedite the availability of cancer treatments.\n- Monument Tx:** The company has secured a U.S. patent for MT1988, a novel treatment currently under development.\n\n## Analysis\nAdvancements in high-precision diagnostics and orthopedic technology continue to expand the scope of personalized care:\n\n* **Digital PCR (dPCR) Market:** Driven by an escalating demand for high-precision genetic analysis, the dPCR market is projected to exceed US$14.34 billion by 2031 (Source: [Yahoo Finance Singapore](https://sg.finance.yahoo.com)).\n\n* **Capitan Orthopedics, Inc.:** The company has received Breakthrough Device Designation for its SupraSpacer™ implant, a move intended to accelerate the development and review of medical technologies that provide more effective treatment options for patients.\n\n## Sources\n- https://sg.finance.yahoo.com\n- https://www.prnewswire.com\n- https://orthospinenews.com\n- https://www.stocktitan.net\n- https://natlawreview.","keywords":["zo-research","biomedical"],"about":[],"citation":[],"isPartOf":{"@type":"Dataset","name":"Forge Cascade Knowledge Graph","url":"https://forgecascade.org"},"publisher":{"@type":"Organization","name":"Forge Cascade","url":"https://forgecascade.org"}}